PEDIATRICS Vol. 94 No. 5 November 1994, pp. A40
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

SAD NEGLECT OF ANTENATAL STEROIDS

While rejoicing in the publication of the OSIRIS trial of surfactant therapy for RDS, the largest randomised trial in neonatology so far, we were sorry to see echoed in the results an apparent reluctance to use a cheap and effective intervention designed to prevent the problem in the first place. The results accord with our finding after review of the data obtained in the course of a collaborative trial in the UK Northern Region Health Authority. We refer to the sad fact that only 15-20% of babies had been offered the protective effect of antenatal steroids despite the fact that it is 20 years since the publication of the first trial to show the effectiveness of this treatment.1